Interestingly, high levels of NEDD9 expression were associated with aggressive breast cancers, including ER−/PR−/Her2− subtype of invasive ductal breast cancers and Her2/neu-positive breast cancers (Table 1 and Table S1). Here, NEDD9 is linked to breast carcinoma.